These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1338 related items for PubMed ID: 25315404

  • 21. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [Abstract] [Full Text] [Related]

  • 22. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H, Niino M, Onizuka Y, Hiramatsu K, Hase M, Yun J, Matta A, Torii S.
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [Abstract] [Full Text] [Related]

  • 23. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S, Mikulskis A, Gold R, Fox RJ, Dawson KT, Amaravadi L.
    Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
    [Abstract] [Full Text] [Related]

  • 24. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A, NTD Study Group.
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [Abstract] [Full Text] [Related]

  • 25. Assessment of the minimum clinically important difference in pain, disability, and quality of life after anterior cervical discectomy and fusion: clinical article.
    Parker SL, Godil SS, Shau DN, Mendenhall SK, McGirt MJ.
    J Neurosurg Spine; 2013 Feb; 18(2):154-60. PubMed ID: 23176164
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
    Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL.
    Neurol Ther; 2017 Dec; 6(2):175-187. PubMed ID: 28770420
    [Abstract] [Full Text] [Related]

  • 27. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E, Joutseno J, Sumelahti ML.
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [Abstract] [Full Text] [Related]

  • 28. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Mar; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 29. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ, Montgomery SM, Griffiths MJ, Bergvall N, Adlard N.
    J Med Econ; 2015 Mar; 18(11):874-85. PubMed ID: 26055952
    [Abstract] [Full Text] [Related]

  • 30. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [Abstract] [Full Text] [Related]

  • 31. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
    Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, Sheikh SI, Seidman E, Dawson KT.
    Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778
    [Abstract] [Full Text] [Related]

  • 32. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
    Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.
    CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
    [Abstract] [Full Text] [Related]

  • 33. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N, Cella D.
    Mult Scler; 2020 Jul 20; 26(8):955-963. PubMed ID: 31144568
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
    Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R.
    Ann Clin Transl Neurol; 2015 Feb 20; 2(2):103-18. PubMed ID: 25750916
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.
    Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.
    J Comp Eff Res; 2017 Jun 20; 6(4):313-323. PubMed ID: 28350241
    [Abstract] [Full Text] [Related]

  • 39. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.
    Mult Scler Relat Disord; 2016 Nov 20; 10():204-212. PubMed ID: 27919491
    [Abstract] [Full Text] [Related]

  • 40. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Mokliatchouk O, Jiang X, Lyons J, Kapadia S, Miller C.
    Mult Scler; 2022 Apr 20; 28(5):801-816. PubMed ID: 34465252
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.